Vaccine Impact Ratios for Effective Immunization Planning and Prioritization

A modelling study published in The Lancet on May 16, 2026, provides a new framework for comparing the health impacts of various vaccines across 117 countries. The research introduces vaccine impact ratios designed to assist national immunization programs in the prioritization and planning of their vaccine portfolios.

The study, titled Quantifying relative health impact across Gavi, the Vaccine Alliance’s portfolio in 117 countries at the subregional level: a modelling study, focuses on the necessity of robust metrics to guide decision-making. As country vaccine budgets become a more central consideration in public health planning, the ability to compare the relative effectiveness of different vaccines has become increasingly important.

By analyzing data at the subregional level, the modelling study offers a more detailed perspective on health impacts than broad national data alone. This granularity is intended to help health officials identify where specific vaccines may provide the highest relative benefit within different geographic or demographic areas.

The research emphasizes that having standardized metrics is essential for informing the discussions that shape national health policies. These ratios provide a method for quantifying how different vaccines in a portfolio contribute to overall health outcomes, allowing for a more structured approach to resource allocation.

The vaccine impact ratios presented in this study can be used to complement other evidence to support effective planning and prioritisation in national immunisation programmes.

The Lancet

The study positions these impact ratios as a complementary tool rather than a sole determinant for policy. They are intended to be used alongside other existing evidence to ensure that immunization strategies are both effective and sustainable within the constraints of available budgets.

The focus on 117 countries suggests a broad application of the model, aiming to provide a scalable way for governments to evaluate their vaccine portfolios. By quantifying relative health impacts, the study seeks to reduce ambiguity in the selection and implementation of vaccines in Gavi-supported contexts.

This approach to quantification is designed to support the broader goal of optimizing public health outcomes through data-driven prioritization, ensuring that the most impactful interventions are prioritized in national health budgets.